2005, FDA, Pharmacology and Safety

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2005

FDA

Pharmacology

Safety

The future of medical cannabis development in Europe

European Pharmaceutical Review

JULY 13, 2023

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).

Medical

Medical Food and Drug Administration Pharmacology Medicine

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

Food and Drug Administration

Food and Drug Administration Safety Patients Leads

Pharma Rep Focus

The future of medical cannabis development in Europe

Paving the way for anti-Abeta active immunotherapy

Stay Connected